3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Tumor-Agnostic
3
Sarcoma
1
Gynecologic
1
Gastrointestinal
1
Breast
1
Conditions
Breast Neoplasms
12
Triple Negative Breast Neoplasms
2
Breast Neoplasms, Male
2
Stomach Neoplasms
1
Pathologic Complete Response
1
Ovarian Neoplasms
1
Neoplasms
1
Hemangiosarcoma
1
Glioblastoma
1
Esophageal Neoplasms
1
Interventions
Paclitaxel
26
pembrolizumab
24
Docetaxel
20
Capecitabine
19
Fulvestrant
17
Trastuzumab
16
Anastrozole
15
Cyclophosphamide
14
Lapatinib
13
Letrozole
11
Carboplatin
11
Radiotherapy
10
Doxorubicin
10
palbociclib
9
Therapeutics
9
Nivolumab
9
Exercise
9
Gemcitabine
8
Cisplatin
8
Blood Specimen Collection
8
Tamoxifen
7
Bevacizumab
7
liposomal doxorubicin
6
exemestane
6
abemaciclib
6
Vinorelbine
6
Standard of Care
6
Fluorouracil
6
ribociclib
5
atezolizumab
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms
×
MK 2206
×
Breast
×
Clear all
NCT01042379
2026-05-06
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2
Recruiting
5,000 enrolled